Immuno‐oncological role of 20S proteasome alpha‐subunit 3 in aggravating the progression of esophageal squamous cell carcinoma

Abstract

PSMA3, a member of the proteasome subunit, has been shown to play a major player in protein degradation. Reportedly, PSMA3 functions as a negative regulator in various cancers including colon, pancreatic and gastric cancers. However, the contributions of PSMA3 to the progression of esophageal squamous cell carcinoma (ESCC) and the underlying mechanism remain unclear. Therefore, in this study, we investigated whether PSMA3 is involved in ESCC progression and the potential underlying mechanism. The results revealed that PSMA3 was highly expressed in the ESCC tumor tissues and functioned as a negative indicator according to the data from The Cancer Genome Atlas (TCGA)/Gene Expression Omnibus (GEO) datasets and clinical patients' samples. Pathway enrichment analysis showed that PSMA3 was closely correlated with ESCC cancer stemness and the inflammatory response; however, this correlation was absent after knockdown of PSMA3 in vitro. We further demonstrated that PSMA3 suppressed CD8 + T-cells infiltration depending on the C-C motif chemokine ligand 3 (CCL3)/C-C motif chemokine receptor 5 (CCR5) axis. Collectively, these results demonstrate the role of PSMA3 in ESCC cancer stemness and the negative regulation of CD8 T-cells infiltration mediated by PSMA3. The results of this study may provide a potential target for the immuno-oncology effect of PSMA3 in ESCC therapy.

Identification of Potential Biomarkers Using Integrative Approach: A Case Study of ESCC

“…According to Liu et al [ 45 ], vaccinia-related kinase (VRK) serine/threonine kinase 1 promotes CDDP resistance through c-MYC by activating c-Jun and potentiating a malignant phenotype in ESCC. Liu et al [ 46 ] provided a potential target for the immuno-oncology effect of roteasome alpha-subunit 3 ( PSMA3 ) in ESCC therapy. Wang et al [ 47 ] detected the major role of Pleckstrin-2 ( PLEK2 ) in driving metastasis and chemoresistance in ESCC by regulating LCN2.…”